2021 Form 10-K Financial Statement

#000121390021065464 Filed on December 15, 2021

View on sec.gov

Income Statement

Concept 2021 2020
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.29M $8.900M
YoY Change 26.87% 27.14%
% of Gross Profit
Research & Development $12.24M $8.810M
YoY Change 38.94% 2.44%
% of Gross Profit
Depreciation & Amortization $1.490K $0.00
YoY Change
% of Gross Profit
Operating Expenses $23.53M $17.71M
YoY Change 32.87% 13.53%
Operating Profit -$23.53M
YoY Change
Interest Expense $251.0K $50.00K
YoY Change 401.98% 25.0%
% of Operating Profit
Other Income/Expense, Net $59.92K $110.0K
YoY Change -45.53%
Pretax Income -$23.05M -$17.55M
YoY Change 31.36% 12.79%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$23.05M -$17.55M
YoY Change 31.36% 12.79%
Net Earnings / Revenue
Basic Earnings Per Share -$0.23
Diluted Earnings Per Share -$212.3K -$448.0K
COMMON SHARES
Basic Shares Outstanding 108.6M shares
Diluted Shares Outstanding 108.6M shares

Balance Sheet

Concept 2021 2020
SHORT-TERM ASSETS
Cash & Short-Term Investments $70.07M $13.86M
YoY Change 405.58% 75.67%
Cash & Equivalents $70.07M $13.86M
Short-Term Investments
Other Short-Term Assets $2.741M $120.0K
YoY Change 2184.5% 140.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $72.81M $13.98M
YoY Change 420.85% 76.07%
LONG-TERM ASSETS
Property, Plant & Equipment $829.9K $990.0K
YoY Change -16.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $38.06K $60.00K
YoY Change -36.57% 0.0%
Total Long-Term Assets $69.61M $29.79M
YoY Change 133.68% 3.4%
TOTAL ASSETS
Total Short-Term Assets $72.81M $13.98M
Total Long-Term Assets $69.61M $29.79M
Total Assets $142.4M $43.77M
YoY Change 225.4% 19.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.277M $1.860M
YoY Change -31.34% -31.37%
Accrued Expenses $2.705M $2.070M
YoY Change 30.69% 20.35%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $170.0K
YoY Change -100.0% 0.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.982M $4.100M
YoY Change -2.87% -11.06%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $160.0K
YoY Change -100.0%
Other Long-Term Liabilities $678.2K $860.0K
YoY Change -21.14%
Total Long-Term Liabilities $678.2K $1.020M
YoY Change -33.51%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.982M $4.100M
Total Long-Term Liabilities $678.2K $1.020M
Total Liabilities $10.25M $10.10M
YoY Change 1.45% 5.32%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $132.2M $33.67M
YoY Change
Total Liabilities & Shareholders Equity $142.4M $43.77M
YoY Change 225.4% 19.1%

Cashflow Statement

Concept 2021 2020
OPERATING ACTIVITIES
Net Income -$23.05M -$17.55M
YoY Change 31.36% 12.79%
Depreciation, Depletion And Amortization $1.490K $0.00
YoY Change
Cash From Operating Activities -$24.25M -$16.93M
YoY Change 43.24% 36.09%
INVESTING ACTIVITIES
Capital Expenditures -$40.01M $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$40.01M $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 120.5M 22.90M
YoY Change 426.07% 105.38%
NET CHANGE
Cash From Operating Activities -24.25M -16.93M
Cash From Investing Activities -40.01M 0.000
Cash From Financing Activities 120.5M 22.90M
Net Change In Cash 56.21M 5.970M
YoY Change 841.59% -562.79%
FREE CASH FLOW
Cash From Operating Activities -$24.25M -$16.93M
Capital Expenditures -$40.01M $0.00
Free Cash Flow $15.76M -$16.93M
YoY Change -193.07% 36.09%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Entity Public Float
EntityPublicFloat
218000000 USD
CY2021Q3 us-gaap Interest Payable Current
InterestPayableCurrent
USD
CY2021Q3 us-gaap Notes Payable Current
NotesPayableCurrent
USD
CY2021 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
shares
CY2020 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
shares
CY2020 ctxr Increase Decrease In Other Deposit
IncreaseDecreaseInOtherDeposit
USD
CY2021 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
USD
CY2020 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
USD
CY2020 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
USD
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
USD
CY2020 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
USD
CY2021 ctxr Operating Lease Rightofuse Asset And Liability Recorded Upon Adoption
OperatingLeaseRightofuseAssetAndLiabilityRecordedUponAdoption
USD
CY2021Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
USD
CY2020Q3 us-gaap Minority Interest
MinorityInterest
USD
CY2020 us-gaap Revenues
Revenues
USD
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
USD
CY2021Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
USD
CY2020Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
USD

Files In Submission

Name View Source Status
0001213900-21-065464-index-headers.html Edgar Link pending
0001213900-21-065464-index.html Edgar Link pending
0001213900-21-065464.txt Edgar Link pending
0001213900-21-065464-xbrl.zip Edgar Link pending
ctxr-20210930.xsd Edgar Link pending
ctxr-20210930_cal.xml Edgar Link unprocessable
ctxr-20210930_def.xml Edgar Link unprocessable
ctxr-20210930_lab.xml Edgar Link unprocessable
ctxr-20210930_pre.xml Edgar Link unprocessable
f10k2021ex-21_citiuspharma.htm Edgar Link pending
f10k2021ex10-29_citiuspharma.htm Edgar Link pending
f10k2021ex10-30_citiuspharma.htm Edgar Link pending
f10k2021ex10-31_citiuspharma.htm Edgar Link pending
f10k2021ex10-32_citiuspharma.htm Edgar Link pending
f10k2021ex10-33_citiuspharma.htm Edgar Link pending
f10k2021ex23-1_citiuspharma.htm Edgar Link pending
f10k2021ex31-1_citiuspharma.htm Edgar Link pending
f10k2021ex31-2_citiuspharma.htm Edgar Link pending
f10k2021ex32-1_citiuspharma.htm Edgar Link pending
f10k2021_citiuspharma.htm Edgar Link pending
f10k2021_citiuspharma_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending